Clinical Trials Update provides you with latest news about clinical trials conducted by companies located in Medicon Valley and gives insight to progress in studies, results and possible indications. 

ALK-Abelló Present Successful Phase III Clinical Study Results with GRAZAX in Children

16 March - This week ALK-Abello presented successful Phase III clinical study results with GRAZAX in children. More than 250 patients participated in the randomized, double blind, placebo controlled GRAZAX GT-12 study. The main results showed that in the grass pollen season (using a threshold of 30 grains/m3), GRAZAX reduced hay fever symptoms by 28% and reduced the need for symptom relieving medication by 65% (median values). The results show corresponding effect to the results from the largest clinical trial programme ever conducted within allergy immunotherapy in adults which led to a European marketing approval for adults in 2006.

Read more